Ignite Creation Date:
2024-05-06 @ 3:21 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04604132
Status:
TERMINATED
Last Update Posted:
2024-04-04
First Post:
2020-10-21
Brief Title:
Derazantinib Alone or in Combination With Paclitaxel Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Gastric Adenocarcinoma |
Keywords:
| Name | View |
|---|---|
| solid tumor | View |
| gastric cancer | View |
| gastro-esophageal adenocarcinoma | View |
| adenocarcinoma of the stomach or gastro-esophageal junction | View |
| fibroblast growth factor receptor | View |
| FGFR genetic aberration | View |
| targeted therapy | View |
| derazantinib | View |
| atezolizumab | View |
| Tecentriq | View |
| paclitaxel | View |
| ramucirumab | View |
| Cyramza | View |